Market Closed -
Xetra
11:35:06 2024-05-31 am EDT
5-day change
1st Jan Change
166.5
EUR
+1.12%
-0.75%
+15.54%
Merck : Q1 24 Financial Statement
May 16, 2024 at 12:53 pm EDT
Merck KGaA, Darmstadt, Germany
Contact
Merck KGaA, Darmstadt, Germany
Investor Relations
Frankfurter Strasse 250
64293 Darmstadt
Germany
Phone: +49 6151 72 3321
e-mail: investor.relations@merckgroup.com
www.merckgroup.com
WKN:
659990
ISIN:
DE0006599905
Ticker Symbol:
MRK
Financial Statements Q1 2023 - Q1 2024
Content
1 Income statements
1.1
Group, quarterly
1.2
Life Science, quarterly
1.3
Healthcare, quarterly
1.4
Electronics, quarterly
1.5
Corporate/Others, quarterly
1.6
Financial result, quarterly
2 Cash flow statement
3 Balance sheet
Summary
Net sales/Net sales growth by business sector Merck KGaA, Darmstadt, Germany
2023
2024
2023
2024
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Group
5,293.0
5,302.4
10,595.3
5,173.1
15,768.4
5,224.5
10,397.6
20,992.9
5,119.8
Group
YoY ∆
95.2
-266.0
-170.8
-632.7
-803.5
-435.9
-1,068.5
-1,239.3
-173.2
YoY %
1.8%
-4.8%
-1.6%
-10.9%
-4.8%
-7.7%
-9.3%
-5.6%
-3.3%
Acquisitions ∆
9.4
3.2
12.6
3.1
15.6
3.4
6.4
19.0
-0.6
Acquisitions %
0.2%
0.1%
0.1%
0.1%
0.1%
0.1%
0.1%
0.1%
0.0%
Fx ∆
43.5
-207.4
-163.9
-395.5
-559.4
-342.4
-737.9
-901.8
-108.3
Fx %
0.8%
-3.7%
-1.5%
-6.8%
-3.4%
-6.0%
-6.4%
-4.1%
-2.0%
Organic ∆
42.3
-61.8
-19.5
-240.2
-259.7
-96.9
-337.1
-356.6
-64.3
Organic %
0.8%
-1.1%
-0.2%
-4.1%
-1.6%
-1.7%
-2.9%
-1.6%
-1.2%
Life Science
2,486.8
2,353.5
4,840.3
2,190.9
7,031.2
2,249.4
4,440.2
9,280.5
2,143.7
Life Science
YoY ∆
41.4
-294.2
-252.9
-489.9
-742.7
-357.1
-846.9
-1,099.8
-343.1
YoY %
1.7%
-11.1%
-5.0%
-18.3%
-9.6%
-13.7%
-16.0%
-10.6%
-13.8%
Acquisitions ∆
6.3
-0.2
6.0
0.1
6.2
0.1
0.2
6.3
0.0
Acquisitions %
0.3%
0.0%
0.1%
0.0%
0.1%
0.0%
0.0%
0.1%
0.0%
Fx ∆
20.9
-64.6
-43.7
-135.7
-179.4
-105.3
-240.9
-284.6
-30.4
Fx %
0.9%
-2.4%
-0.9%
-5.1%
-2.3%
-4.0%
-4.6%
-2.7%
-1.2%
Organic ∆
14.2
-229.4
-215.2
-354.3
-569.6
-251.9
-606.2
-821.5
-312.7
Organic %
0.6%
-8.7%
-4.2%
-13.2%
-7.3%
-9.7%
-11.5%
-7.9%
-12.6%
Healthcare
1,905.5
2,049.5
3,955.0
2,066.3
6,021.3
2,031.9
4,098.2
8,053.2
2,047.7
Healthcare
YoY ∆
110.5
125.3
235.9
-23.0
212.8
1.6
-21.4
214.5
142.2
YoY %
6.2%
6.5%
6.3%
-1.1%
3.7%
0.1%
-0.5%
2.7%
7.5%
Acquisitions ∆
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Acquisitions %
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Fx ∆
14.8
-104.6
-89.8
-178.1
-267.9
-185.7
-363.8
-453.6
-49.3
Fx %
0.8%
-5.4%
-2.4%
-8.5%
-4.6%
-9.1%
-8.8%
-5.8%
-2.6%
Organic ∆
95.7
229.9
325.7
155.1
480.8
187.3
342.4
668.1
191.5
Organic %
5.3%
11.9%
8.8%
7.4%
8.3%
9.2%
8.3%
8.5%
10.1%
Electronics
900.7
899.3
1,800.0
915.9
2,715.9
943.2
1,859.1
3,659.2
928.4
Electronics
YoY ∆
-56.7
-97.1
-153.8
-119.8
-273.6
-80.4
-200.2
-354.0
27.7
YoY %
-5.9%
-9.7%
-7.9%
-11.6%
-9.2%
-7.9%
-9.7%
-8.8%
3.1%
Acquisitions ∆
3.1
3.4
6.5
2.9
9.5
3.3
6.2
12.8
-0.6
Acquisitions %
0.3%
0.3%
0.3%
0.3%
0.3%
0.3%
0.3%
0.3%
-0.1%
Fx ∆
7.7
-38.2
-30.4
-81.7
-112.1
-51.4
-133.2
-163.6
-28.6
Fx %
0.8%
-3.8%
-1.6%
-7.9%
-3.8%
-5.0%
-6.5%
-4.1%
-3.2%
Organic ∆
-67.6
-62.3
-129.9
-41.0
-170.9
-32.3
-73.3
-203.2
56.8
Organic %
-7.1%
-6.3%
-6.7%
-4.0%
-5.7%
-3.2%
-3.6%
-5.1%
6.3%
EBITDA pre by business sector Merck KGaA, Darmstadt, Germany
2023
2024
2023
2024
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Group
1,587.0
1,553.3
3,140.3
1,445.6
4,585.9
1,293.0
2,738.7
5,878.9
1,453.9
Group
% Margin
30.0%
29.3%
29.6%
27.9%
29.1%
24.7%
26.3%
28.0%
28.4%
YoY ∆
-41.8
-228.7
-270.5
-364.8
-635.3
-334.9
-699.7
-970.2
-133.1
YoY %
-2.6%
-12.8%
-7.9%
-20.2%
-12.2%
-20.6%
-20.3%
-14.2%
-8.4%
Acquisitions ∆
-6.1
-3.0
-9.1
-5.7
-14.9
-5.0
-10.7
-19.9
0.0
Acquisitions %
-0.4%
-0.2%
-0.3%
-0.3%
-0.3%
-0.3%
-0.3%
-0.3%
0.0%
Fx ∆
-7.7
-101.2
-108.9
-120.1
-229.0
-106.4
-226.5
-335.4
-50.7
Fx %
-0.5%
-5.7%
-3.2%
-6.6%
-4.4%
-6.5%
-6.6%
-4.9%
-3.2%
Organic ∆
-27.9
-124.6
-152.5
-239.0
-391.5
-223.5
-462.5
-615.0
-82.4
Organic %
-1.7%
-7.0%
-4.5%
-13.2%
-7.5%
-13.7%
-13.5%
-9.0%
-5.2%
Life Science
900.6
711.9
1,612.5
615.1
2,227.6
592.0
1,207.1
2,819.6
611.2
Life Science
% Margin
36.2%
30.2%
33.3%
28.1%
31.7%
26.3%
27.2%
30.4%
28.5%
YoY ∆
-26.5
-293.8
-320.3
-361.3
-681.6
-258.3
-619.6
-939.9
-289.4
YoY %
-2.9%
-29.2%
-16.6%
-37.0%
-23.4%
-30.4%
-33.9%
-25.0%
-32.1%
Acquisitions ∆
-4.3
1.6
-2.7
-7.0
-9.8
-1.4
-8.5
-11.2
0.0
Acquisitions %
-0.5%
0.2%
-0.1%
-0.7%
-0.3%
-0.2%
-0.5%
-0.3%
0.0%
Fx ∆
-9.4
-32.8
-42.2
-46.6
-88.8
-35.6
-82.3
-124.4
-16.6
Fx %
-1.0%
-3.3%
-2.2%
-4.8%
-3.1%
-4.2%
-4.5%
-3.3%
-1.8%
Organic ∆
-12.8
-262.6
-275.4
-307.6
-583.0
-221.3
-528.9
-804.3
-272.8
Organic %
-1.4%
-26.1%
-14.2%
-31.5%
-20.0%
-26.0%
-29.0%
-21.4%
-30.3%
Healthcare
589.6
703.6
1,293.2
685.4
1,978.5
564.5
1,249.9
2,543.1
708.0
Healthcare
% Margin
30.9%
34.3%
32.7%
33.2%
32.9%
27.8%
30.5%
31.6%
34.6%
YoY ∆
60.5
100.0
160.5
-25.5
135.0
-68.5
-94.0
66.5
118.4
YoY %
11.4%
16.6%
14.2%
-3.6%
7.3%
-10.8%
-7.0%
2.7%
20.1%
Acquisitions ∆
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Acquisitions %
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Fx ∆
4.9
-83.8
-78.8
-148.0
-226.8
-129.0
-277.0
-355.8
-48.6
Fx %
0.9%
-13.9%
-7.0%
-20.8%
-12.3%
-20.4%
-20.6%
-14.4%
-8.2%
Organic ∆
55.6
183.8
239.3
122.5
361.8
60.5
183.0
422.3
167.0
Organic %
10.5%
30.4%
21.1%
17.2%
19.6%
9.6%
13.6%
17.1%
28.3%
Electronics
237.3
261.7
499.1
207.9
707.0
206.0
413.9
913.0
236.6
Electronics
% Margin
26.4%
29.1%
27.7%
22.7%
26.0%
21.8%
22.3%
25.0%
25.5%
YoY ∆
-52.0
-31.3
-83.3
-93.7
-177.1
-102.2
-195.9
-279.2
-0.7
YoY %
-18.0%
-10.7%
-14.3%
-31.1%
-20.0%
-33.1%
-32.1%
-23.4%
-0.3%
Acquisitions ∆
-1.3
-1.6
-2.9
-2.1
-5.0
-3.2
-5.4
-8.3
0.0
Acquisitions %
-0.4%
-0.5%
-0.5%
-0.7%
-0.6%
-1.1%
-0.9%
-0.7%
0.0%
Fx ∆
6.6
-14.5
-7.9
-37.9
-45.8
-20.9
-58.8
-66.7
-10.0
Fx %
2.3%
-4.9%
-1.4%
-12.6%
-5.2%
-6.8%
-9.6%
-5.6%
-4.2%
Organic ∆
-57.3
-15.3
-72.5
-53.6
-126.2
-78.0
-131.7
-204.2
9.3
Organic %
-19.8%
-5.2%
-12.5%
-17.8%
-14.3%
-25.3%
-21.6%
-17.1%
3.9%
Corporate/Others
-140.5
-123.9
-264.5
-62.7
-327.2
-69.5
-132.3
-396.7
-101.9
Corporate/Others
YoY ∆
-23.7
-3.6
-27.3
115.6
88.3
94.1
209.8
182.4
38.6
YoY %
20.3%
3.0%
11.5%
-64.8%
-21.3%
-57.5%
-61.3%
-31.5%
-27.5%
Due to rounding the sum of individual values may not add up to totals presented.
Group
Income Statement Merck KGaA, Darmstadt, Germany
Group
2023
2024
Change YoY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Net sales
5,293.0
5,302.4
10,595.3
5,173.1
15,768.4
5,224.5
10,397.6
20,992.9
5,119.8
-3.3%
Cost of sales
-1,972.5
-2,138.9
-4,111.4
-2,161.8
-6,273.2
-2,327.3
-4,489.1
-8,600.5
-2,110.6
7.0%
thereof amortization of intangible assets
-48.2
-46.2
-94.3
-40.3
-134.7
-38.6
-78.9
-173.2
-38.2
-20.6%
Gross profit
3,320.4
3,163.5
6,483.9
3,011.3
9,495.2
2,897.2
5,908.5
12,392.4
3,009.2
-9.4%
in % of net sales
62.7%
59.7%
61.2%
58.2%
60.2%
55.5%
56.8%
59.0%
58.8%
SG&A
-1,688.2
-1,593.6
-3,281.8
-1,447.0
-4,728.8
-1,609.3
-3,056.3
-6,338.1
-1,497.3
-11.3%
in % of net sales
31.9%
30.1%
31.0%
28.0%
30.0%
30.8%
29.4%
30.2%
29.2%
Marketing and selling expenses
-1,109.1
-1,139.4
-2,248.5
-1,104.3
-3,352.9
-1,157.5
-2,261.8
-4,510.4
-1,087.1
-2.0%
thereof amortization of intangible assets (M&S)
-151.3
-148.9
-300.2
-146.7
-446.9
-149.3
-296.0
-596.2
-144.7
-4.3%
Administration expenses
-357.9
-345.0
-702.9
-312.0
-1,014.9
-377.4
-689.4
-1,392.3
-331.7
-7.3%
Impairment losses and reversals (IFRS 9)
-2.2
-9.7
-11.9
-28.3
-40.2
-10.3
-38.6
-50.5
1.0
n.m.
Other operating expenses/income
-219.0
-99.4
-318.4
-2.3
-320.8
-64.1
-66.5
-384.9
-79.5
-63.7%
Impairments**
-9.7
-36.9
-46.6
-3.8
-50.4
-36.9
-40.7
-87.2
-0.5
-95.1%
Research and development costs
-597.3
-600.4
-1,197.7
-581.1
-1,778.8
-666.5
-1,247.5
-2,445.2
-580.6
-2.8%
in % of net sales
11.3%
11.3%
11.3%
11.2%
11.3%
12.8%
12.0%
11.6%
11.3%
thereof amortization of intangible assets (R&D)
-4.4
-3.0
-7.4
-3.2
-10.6
-3.4
-6.5
-14.0
-3.3
-25.6%
EBIT
1,035.0
969.5
2,004.4
983.2
2,987.7
621.5
1,604.7
3,609.1
931.3
-10.0%
in % of net sales
19.6%
18.3%
18.9%
19.0%
18.9%
11.9%
15.4%
17.2%
18.2%
Depreciation and amortization
455.5
482.3
937.8
435.2
1,373.0
506.7
941.9
1,879.7
453.5
-0.4%
EBITDA
1,490.5
1,451.8
2,942.3
1,418.4
4,360.7
1,128.2
2,546.6
5,488.9
1,384.8
-7.1%
in % of net sales
28.2%
27.4%
27.8%
27.4%
27.7%
21.6%
24.5%
26.1%
27.0%
EBITDA pre
1,587.0
1,553.3
3,140.3
1,445.6
4,585.9
1,293.0
2,738.7
5,878.9
1,453.9
-8.4%
in % of net sales
30.0%
29.3%
29.6%
27.9%
29.1%
24.7%
26.3%
28.0%
28.4%
Financial result
-22.7
-75.7
-98.4
-46.0
-144.3
19.1
-26.8
-125.2
-32.2
42.1%
Profit before income tax from continuing operations
1,012.3
893.8
1,906.1
937.3
2,843.3
640.6
1,577.9
3,483.9
899.1
-11.2%
Income tax
-212.6
-187.7
-400.3
-196.8
-597.1
-53.0
-249.8
-650.1
-199.6
-6.1%
Income tax rate
21.0%
21.0%
21.0%
21.0%
21.0%
8.3%
15.8%
18.7%
22.2%
Profit after tax from continuing operations
799.7
706.1
1,505.8
740.4
2,246.2
587.6
1,328.0
2,833.8
699.5
-12.5%
Profit after tax from discontinued operations
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Profit after tax
799.7
706.1
1,505.8
740.4
2,246.2
587.6
1,328.0
2,833.8
699.5
-12.5%
of which: attributable to Merck KGaA shareholders (net income)
796.2
703.6
1,499.8
738.7
2,238.4
585.3
1,323.9
2,823.7
694.2
-12.8%
of which: attributable to non-controlling interests
3.5
2.5
6.0
1.8
7.8
2.3
4.1
10.1
5.2
48.4%
EPS in €
1.83
1.62
3.45
1.70
5.15
1.35
3.05
6.49
1.60
-12.6%
thereof from continuing operations
1.83
1.62
3.45
1.70
5.15
1.35
3.05
6.49
1.60
-12.6%
thereof from discontinued operations
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
n.m.
EPS pre in €*
2.36
2.20
4.57
2.07
6.64
1.85
3.92
8.49
2.06
-12.7%
Number of theoretical shares in million
434.8
434.8
434.8
434.8
434.8
434.8
434.8
434.8
434.8
Reconciliation to EBITDA pre
EBITDA
1,490.5
1,451.8
2,942.3
1,418.4
4,360.7
1,128.2
2,546.6
5,488.9
1,384.8
-7.1%
Adjustments
thereof: Cost of Sales
2.7
4.6
7.2
10.4
17.6
24.9
35.3
42.6
4.1
53.8%
thereof: Marketing and selling expenses
-0.9
5.4
4.5
8.0
12.4
31.9
39.9
44.3
9.1
n.m.
thereof: Administration expenses
71.7
41.9
113.6
33.9
147.5
98.3
132.2
245.8
43.0
-40.0%
thereof: Other operating expenses/income
30.9
42.1
73.0
-25.5
47.5
2.9
-22.6
50.5
7.5
-75.7%
thereof: Research and development
-7.9
7.6
-0.3
0.5
0.1
6.8
7.2
6.9
5.4
n.m.
Total
96.5
101.5
198.0
27.2
225.2
164.9
192.1
390.1
69.1
-28.4%
EBITDA pre
1,587.0
1,553.3
3,140.3
1,445.6
4,585.9
1,293.0
2,738.7
5,878.9
1,453.9
-8.4%
Due to rounding the sum of individual values may not add up to totals presented.
* For continuing operations.
** Only reflects impairments classified as adjustments.
Group pre
Reconciliation to EBITDA, EBITDA pre and EPS pre
Group
2023
2024
Change YoY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
a) Reconciliation to EBITDA and EBITDA pre
EBITDA
EBIT
1,035.0
969.5
2,004.4
983.2
2,987.7
621.5
1,604.7
3,609.1
931.3
-10.0%
Depreciation and amortization
455.5
482.3
937.8
435.2
1,373.0
506.7
941.9
1,879.7
453.5
-0.4%
Regular depreciation and amortization*
242.0
243.2
485.2
241.1
726.3
266.9
508.0
993.2
257.6
6.5%
Impairments not adjusted
0.0
4.2
4.2
0.0
4.2
11.8
11.8
16.0
9.2
>1.000%
Amortization of purchased intangible assets
203.8
198.1
401.9
190.3
592.2
191.2
381.5
783.3
186.2
-8.6%
Impairments (net)**
9.7
36.9
46.6
3.8
50.4
36.9
40.7
87.2
0.5
-95.1%
Total
1,490.5
1,451.8
2,942.3
1,418.4
4,360.7
1,128.2
2,546.6
5,488.9
1,384.8
-7.1%
Adjustments
Acquisition costs
9.2
4.8
14.0
3.7
17.7
0.8
4.4
18.5
2.5
-72.7%
Restructuring costs
44.3
39.3
83.6
24.6
108.2
140.3
164.9
248.5
44.6
0.7%
Integration costs/IT costs
23.5
27.1
50.6
28.8
79.4
39.0
67.8
118.4
17.4
-26.1%
Gain (-)/ losses (+) on the divestment of businesses
0.3
17.1
17.4
-48.8
-31.4
-20.1
-68.8
-51.4
-4.8
n.m.
Other one-time costs
19.2
13.2
32.4
18.9
51.3
4.8
23.7
56.1
9.4
-51.2%
Total
96.5
101.5
198.0
27.2
225.2
164.9
192.1
390.1
69.1
-28.4%
EBITDA pre
1,587.0
1,553.3
3,140.3
1,445.6
4,585.9
1,293.0
2,738.7
5,878.9
1,453.9
-8.4%
b) Reconciliation to EPS pre
1) Reconciliation starting from EBITDA pre
EBITDA pre
1,587.0
1,553.3
3,140.3
1,445.6
4,585.9
1,293.0
2,738.7
5,878.9
1,453.9
-8.4%
Regular depreciation and amortization*
-242.0
-243.2
-485.2
-241.1
-726.3
-266.9
-508.0
-993.2
-257.6
6.5%
Impairments not adjusted
0.0
-4.2
-4.2
0.0
-4.2
-11.8
-11.8
-16.0
-9.2
>1.000%
Financial result
-22.7
-75.7
-98.4
-46.0
-144.3
19.1
-26.8
-125.2
-32.2
42.1%
Adjustments within Financial result
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Profit before income tax pre
1,322.3
1,230.2
2,552.5
1,158.5
3,711.1
1,033.5
2,192.1
4,744.6
1,154.8
-12.7%
Income tax pre
-290.9
-270.6
-561.6
-254.9
-816.4
-227.4
-482.3
-1,043.8
-254.1
-12.7%
underlying tax rate
22.0%
22.0%
22.0%
22.0%
22.0%
22.0%
22.0%
22.0%
22.0%
Non-controlling interest
-3.5
-2.5
-6.0
-1.8
-7.8
-2.3
-4.1
-10.1
-5.2
48.4%
Net income pre
1,027.9
957.1
1,984.9
901.9
2,886.8
803.9
1,705.7
3,690.7
895.6
-12.9%
EPS pre in €***
2.36
2.20
4.57
2.07
6.64
1.85
3.92
8.49
2.06
-12.7%
2) Reconciliation starting from Profit before tax
Profit before income tax
1,012.3
893.8
1,906.1
937.3
2,843.3
640.6
1,577.9
3,483.9
899.1
-11.2%
Amortization of purchased intangible assets
203.8
198.1
401.9
190.3
592.2
191.2
381.5
783.3
186.2
-8.6%
Impairments**
9.7
36.9
46.6
3.8
50.4
36.9
40.7
87.2
0.5
-95.1%
Adjustments
Acquisition costs
9.2
4.8
14.0
3.7
17.7
0.8
4.4
18.5
2.5
-72.7%
Restructuring costs
44.3
39.3
83.6
24.6
108.2
140.3
164.9
248.5
44.6
0.7%
Integration costs/IT costs
23.5
27.1
50.6
28.8
79.4
39.0
67.8
118.4
17.4
-26.1%
Gain (-)/ losses (+) on the divestment of businesses
0.3
17.1
17.4
-48.8
-31.4
-20.1
-68.8
-51.4
-4.8
n.m.
Other one-time costs
19.2
13.2
32.4
18.9
51.3
4.8
23.7
56.1
9.4
-51.2%
Adjustments within Financial result
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Total adjustments
96.5
101.5
198.0
27.2
225.2
164.9
192.1
390.1
69.1
-28.4%
Profit before income tax pre
1,322.3
1,230.2
2,552.5
1,158.5
3,711.1
1,033.5
2,192.1
4,744.6
1,154.8
-12.7%
Income tax pre
-290.9
-270.6
-561.6
-254.9
-816.4
-227.4
-482.3
-1,043.8
-254.1
-12.7%
underlying tax rate
22.0%
22.0%
22.0%
22.0%
22.0%
22.0%
22.0%
22.0%
22.0%
Total costs excluded from Net income
231.7
253.5
485.2
163.2
648.4
218.6
381.8
867.0
201.3
-13.1%
Total costs excluded from EPS in €
0.53
0.58
1.12
0.38
1.49
0.50
0.88
1.99
0.46
-13.2%
Non-controlling interest
-3.5
-2.5
-6.0
-1.8
-7.8
-2.3
-4.1
-10.1
-5.2
48.4%
Net income pre
1,027.9
957.1
1,984.9
901.9
2,886.8
803.9
1,705.7
3,690.7
895.6
-12.9%
EPS pre in €***
2.36
2.20
4.57
2.07
6.64
1.85
3.92
8.49
2.06
-12.7%
Number of theoretical shares in million
434.8
434.8
434.8
434.8
434.8
434.8
434.8
434.8
434.8
Due to rounding the sum of individual values may not add up to totals presented.
* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.
** Only reflects impairments classified as adjustments.
*** For continuing operations.
Reconc. Group
Breakdown of depreciation and amortization and adjustments
Group
2023
2024
Change YoY
€ million
Division
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
a) Depreciation and amortization
Regular depreciation and amortization*
all
242.0
243.2
485.2
241.1
726.3
266.9
508.0
993.2
257.6
6.5%
Impairments not adjusted
all
0.0
4.2
4.2
0.0
4.2
11.8
11.8
16.0
9.2
>1.000%
Amortization of purchased intangible assets
Life Science
LS
118.2
115.8
234.0
108.5
342.5
108.8
217.3
451.3
107.8
-8.7%
Healthcare
HC
1.5
1.6
3.2
1.7
4.8
1.7
3.3
6.5
1.6
3.7%
Electronics
EL
84.1
80.6
164.7
80.1
244.8
80.8
160.8
325.6
76.8
-8.7%
Total
203.8
198.1
401.9
190.3
592.2
191.2
381.5
783.3
186.2
-8.6%
Impairments (net)**
all
9.7
36.9
46.6
3.8
50.4
36.9
40.7
87.2
0.5
-95.1%
Total depreciation and amortization
455.5
482.3
937.8
435.2
1,373.0
506.7
941.9
1,879.7
453.5
-0.4%
b) Adjustments
Acquisition costs
9.2
4.8
14.0
3.7
17.7
0.8
4.4
18.5
2.5
-72.7%
Restructuring costs
Life Science
LS
0.4
1.8
2.2
4.3
6.5
23.1
27.4
29.6
18.0
>1.000%
Healthcare
HC
-7.3
12.0
4.7
2.6
7.3
24.2
26.8
31.6
5.3
n.m.
Electronics
EL
2.2
6.9
9.1
9.9
18.9
41.0
50.9
60.0
4.1
88.8%
Corporate and Other
CO
49.0
18.5
67.6
7.9
75.4
52.0
59.8
127.4
17.2
-65.0%
Total
44.3
39.3
83.6
24.6
108.2
140.3
164.9
248.5
44.6
0.7%
Integration costs/IT costs
Integration Cost
LS/EL/CO
1.9
2.0
4.0
2.2
6.1
1.4
3.5
7.5
2.3
18.4%
ERP/HR systems
all
21.6
25.0
46.6
26.7
73.2
37.6
64.3
110.9
15.1
-30.1%
Total
23.5
27.1
50.6
28.8
79.4
39.0
67.8
118.4
17.4
-26.1%
Gain (-)/ losses (+) on the divestment of businesses
Costs related to former business activities
CO
0.0
21.0
21.0
-3.0
18.0
-16.6
-19.6
1.4
0.0
n.m.
Costs related to former business activities
EL
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Sale of CH, Allergopharma and others
HC
0.3
-3.9
-3.6
-45.8
-49.4
-3.4
-49.2
-52.8
-4.8
n.m.
Costs related to former business activities
LS
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Total
0.3
17.1
17.4
-48.8
-31.4
-20.1
-68.8
-51.4
-4.8
n.m.
Other one-time costs
Others
HC
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
LS
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
EL
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
CO
19.2
13.2
32.4
18.9
51.3
4.8
23.7
56.1
9.4
-51.2%
Total
19.2
13.2
32.4
18.9
51.3
4.8
23.7
56.1
9.4
-51.2%
Total adjustments
96.5
101.5
198.0
27.2
225.2
164.9
192.1
390.1
69.1
-28.4%
Due to rounding the sum of individual values may not add up to totals presented.
* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments
** Only reflects impairments classified as adjustments.
Life Science
Income Statement Merck KGaA, Darmstadt, Germany
Life Science
2023
2024
Change YoY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Net sales
2,486.8
2,353.5
4,840.3
2,190.9
7,031.2
2,249.4
4,440.2
9,280.5
2,143.7
-13.8%
Cost of sales
-999.2
-1,078.2
-2,077.5
-1,031.1
-3,108.6
-1,127.6
-2,158.8
-4,236.3
-987.6
-1.2%
thereof amortization of intangible assets
-13.3
-13.5
-26.8
-8.3
-35.1
-7.2
-15.4
-42.2
-7.1
-46.7%
Gross profit
1,487.5
1,275.3
2,762.8
1,159.7
3,922.6
1,121.7
2,281.4
5,044.3
1,156.2
-22.3%
in % of net sales
59.8%
54.2%
57.1%
52.9%
55.8%
49.9%
51.4%
54.4%
53.9%
SG&A
-711.3
-720.8
-1,432.2
-673.2
-2,105.4
-692.4
-1,365.7
-2,797.8
-683.3
-3.9%
in % of net sales
28.6%
30.6%
29.6%
30.7%
29.9%
30.8%
30.8%
30.1%
31.9%
Marketing and selling expenses
-567.5
-566.3
-1,133.8
-555.7
-1,689.5
-555.3
-1,110.9
-2,244.7
-550.6
-3.0%
thereof amortization of intangible assets (M&S)
-101.4
-100.4
-201.8
-98.2
-300.0
-99.5
-197.7
-399.5
-98.7
-2.7%
Administration expenses
-105.0
-102.8
-207.7
-102.7
-310.5
-114.6
-217.4
-425.1
-111.9
6.6%
Impairment losses and reversals (IFRS 9)
-1.1
-1.2
-2.3
-0.1
-2.4
0.3
0.2
-2.1
-1.0
-4.1%
Other operating expenses/income
-37.8
-50.6
-88.3
-14.8
-103.1
-22.8
-37.6
-125.9
-19.7
-47.7%
Impairments**
0.0
-31.9
-31.9
0.0
-31.9
-1.8
-1.8
-33.7
0.0
-100.0%
Research and development costs
-103.8
-99.1
-203.0
-90.4
-293.3
-103.1
-193.4
-396.4
-95.4
-8.1%
in % of net sales
4.2%
4.2%
4.2%
4.1%
4.2%
4.6%
4.4%
4.3%
4.5%
thereof amortization of intangible assets (R&D)
-3.4
-2.0
-5.4
-2.1
-7.5
-2.1
-4.1
-9.5
-2.1
-38.9%
EBIT
672.4
455.3
1,127.7
396.1
1,523.8
326.2
722.3
1,850.0
377.4
-43.9%
in % of net sales
27.0%
19.3%
23.3%
18.1%
21.7%
14.5%
16.3%
19.9%
17.6%
Depreciation and amortization
211.7
243.1
454.8
204.6
659.4
222.0
426.6
881.4
207.4
-2.0%
EBITDA
884.0
698.5
1,582.5
600.7
2,183.3
548.2
1,148.9
2,731.4
584.8
-33.8%
in % of net sales
35.5%
29.7%
32.7%
27.4%
31.1%
24.4%
25.9%
29.4%
27.3%
EBITDA pre
900.6
711.9
1,612.5
615.1
2,227.6
592.0
1,207.1
2,819.6
611.2
-32.1%
in % of net sales
36.2%
30.2%
33.3%
28.1%
31.7%
26.3%
27.2%
30.4%
28.5%
Reconciliation to EBITDA pre
EBITDA
884.0
698.5
1,582.5
600.7
2,183.3
548.2
1,148.9
2,731.4
584.8
-33.8%
Adjustments
thereof: Cost of Sales
0.2
-0.1
0.1
2.8
3.0
3.2
6.1
6.2
0.8
276.6%
thereof: Marketing and selling expenses
-1.2
0.3
-0.9
0.3
-0.6
12.9
13.2
12.3
5.3
n.m.
thereof: Administration expenses
11.1
12.0
23.0
9.0
32.0
20.8
29.8
52.8
17.1
54.9%
thereof: Other operating expenses/income
6.4
0.5
6.9
2.3
9.2
4.6
6.9
13.8
2.6
-59.8%
thereof: Research and development
0.0
0.7
0.8
0.0
0.8
2.3
2.3
3.1
0.6
>1.000%
Total
16.5
13.4
29.9
14.4
44.4
43.8
58.2
88.2
26.4
59.4%
EBITDA pre
900.6
711.9
1,612.5
615.1
2,227.6
592.0
1,207.1
2,819.6
611.2
-32.1%
Due to rounding the sum of individual values may not add up to totals presented.
** Only reflects impairments classified as adjustments.
Reconc. Life Science
Detailed reconciliation - Life Science
2023
2024
Change YoY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
EBIT
672.4
455.3
1,127.7
396.1
1,523.8
326.2
722.3
1,850.0
377.4
-43.9%
Regular depreciation and amortization*
93.5
95.4
188.9
96.1
285.0
111.4
207.5
396.4
99.5
6.5%
Impairments not adjusted
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-100.0%
Amortization of purchased intangible assets
118.2
115.8
234.0
108.5
342.5
108.8
217.3
451.3
107.8
-8.7%
Impairments (net)**
0.0
31.9
31.9
0.0
31.9
1.8
1.8
33.7
0.0
-100.0%
Total depreciation and amortization
211.7
243.1
454.8
204.6
659.4
222.0
426.6
881.4
207.4
-2.0%
EBITDA
884.0
698.5
1,582.5
600.7
2,183.3
548.2
1,148.9
2,731.4
584.8
-33.8%
Adjustments
Acquisition costs
5.0
-0.3
4.8
0.0
4.8
0.8
0.8
5.6
1.1
-78.4%
Restructuring costs
Restructuring costs
0.4
1.8
2.2
4.3
6.5
23.1
27.4
29.6
18.0
>1.000%
Total
0.4
1.8
2.2
4.3
6.5
23.1
27.4
29.6
18.0
>1.000%
Integration costs/IT costs
Integration Cost
0.7
1.0
1.7
0.9
2.7
0.8
1.7
3.5
1.0
40.1%
ERP/HR systems
10.3
10.9
21.2
9.2
30.4
19.1
28.3
49.5
6.2
-40.4%
Total
11.1
11.8
22.9
10.1
33.1
19.9
30.0
53.0
7.2
-35.0%
Gain (-)/ losses (+) on the divestment of businesses
Costs related to former business activities
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Total
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Other one-time costs
Others
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Total
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Total adjustments
16.5
13.4
29.9
14.4
44.4
43.8
58.2
88.2
26.4
59.4%
EBITDA pre
900.6
711.9
1,612.5
615.1
2,227.6
592.0
1,207.1
2,819.6
611.2
-32.1%
Due to rounding the sum of individual values may not add up to totals presented.
* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.
** Only reflects impairments classified as adjustments.
Healthcare
Income Statement Merck KGaA, Darmstadt, Germany
Healthcare
2023
2024
Change YoY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Net sales
1,905.5
2,049.5
3,955.0
2,066.3
6,021.3
2,031.9
4,098.2
8,053.2
2,047.7
7.5%
Cost of sales
-446.6
-485.9
-932.6
-540.0
-1,472.6
-556.4
-1,096.4
-2,029.0
-543.3
21.6%
thereof amortization of intangible assets
-1.2
-1.2
-2.3
-1.2
-3.5
-1.1
-2.3
-4.6
-1.1
-3.0%
Gross profit
1,458.9
1,563.6
3,022.4
1,526.2
4,548.7
1,475.5
3,001.8
6,024.2
1,504.4
3.1%
in % of net sales
76.6%
76.3%
76.4%
73.9%
75.5%
72.6%
73.2%
74.8%
73.5%
SG&A
-543.9
-546.4
-1,090.2
-481.7
-1,571.9
-570.7
-1,052.4
-2,142.6
-488.9
-10.1%
in % of net sales
28.5%
26.7%
27.6%
23.3%
26.1%
28.1%
25.7%
26.6%
23.9%
Marketing and selling expenses
-380.6
-422.4
-803.0
-405.5
-1,208.5
-459.1
-864.6
-1,667.6
-398.2
4.6%
thereof amortization of intangible assets (M&S)
-0.3
-0.4
-0.7
-0.5
-1.2
-0.5
-0.9
-1.6
-0.4
29.2%
Administration expenses
-75.5
-79.3
-154.8
-78.8
-233.6
-80.2
-159.0
-313.8
-75.2
-0.4%
Impairment losses and reversals (IFRS 9)
-1.0
-8.4
-9.4
-28.4
-37.8
-3.0
-31.3
-40.8
1.9
n.m.
Other operating expenses/income
-86.8
-36.2
-123.0
30.9
-92.0
-28.4
2.5
-120.5
-17.4
-79.9%
Impairments**
0.6
0.0
0.6
0.0
0.6
-10.5
-10.5
-9.9
0.0
-100.0%
Research and development costs
-395.3
-401.5
-796.7
-391.3
-1,188.0
-469.0
-860.3
-1,657.0
-397.5
0.6%
in % of net sales
20.7%
19.6%
20.1%
18.9%
19.7%
23.1%
21.0%
20.6%
19.4%
thereof amortization of intangible assets (R&D)
-0.1
-0.1
-0.1
-0.1
-0.2
-0.1
-0.1
-0.2
-0.1
0.0%
EBIT
519.7
615.8
1,135.5
653.2
1,788.7
435.9
1,089.1
2,224.6
618.0
18.9%
in % of net sales
27.3%
30.0%
28.7%
31.6%
29.7%
21.5%
26.6%
27.6%
30.2%
Depreciation and amortization
72.9
76.2
149.1
70.2
219.4
100.6
170.9
320.0
88.3
21.1%
EBITDA
592.6
692.0
1,284.6
723.4
2,008.1
536.5
1,259.9
2,544.6
706.3
19.2%
in % of net sales
31.1%
33.8%
32.5%
35.0%
33.3%
26.4%
30.7%
31.6%
34.5%
EBITDA pre
589.6
703.6
1,293.2
685.4
1,978.5
564.5
1,249.9
2,543.1
708.0
20.1%
in % of net sales
30.9%
34.3%
32.7%
33.2%
32.9%
27.8%
30.5%
31.6%
34.6%
Reconciliation to EBITDA pre
EBITDA
592.6
692.0
1,284.6
723.4
2,008.1
536.5
1,259.9
2,544.6
706.3
19.2%
Adjustments
thereof: Cost of Sales
0.2
-1.7
-1.5
0.3
-1.3
-0.1
0.2
-1.3
0.1
-52.4%
thereof: Marketing and selling expenses
0.3
4.6
4.9
5.7
10.6
18.3
23.9
28.8
3.7
>1.000%
thereof: Administration expenses
4.0
3.5
7.4
5.1
12.5
7.6
12.6
20.1
1.1
-72.0%
thereof: Other operating expenses/income
0.3
0.3
0.6
-49.3
-48.7
-2.3
-51.5
-51.0
-8.0
n.m.
thereof: Research and development
-7.8
5.0
-2.8
0.2
-2.6
4.5
4.7
1.9
4.8
n.m.
Total
-3.0
11.6
8.6
-38.1
-29.5
28.0
-10.1
-1.5
1.7
n.m.
EBITDA pre
589.6
703.6
1,293.2
685.4
1,978.5
564.5
1,249.9
2,543.1
708.0
20.1%
Due to rounding the sum of individual values may not add up to totals presented.
** Only reflects impairments classified as adjustments.
Reconc. Healthcare
Detailed reconciliation - Healthcare
2023
2024
Change YoY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
EBIT
519.7
615.8
1,135.5
653.2
1,788.7
435.9
1,089.1
2,224.6
618.0
18.9%
Regular depreciation and amortization*
71.9
70.4
142.3
68.5
210.9
76.7
145.3
287.6
77.7
8.0%
Impairments not adjusted
0.0
4.2
4.2
0.0
4.2
11.8
11.8
16.0
9.0
>1.000%
Amortization of purchased intangible assets
1.5
1.6
3.2
1.7
4.8
1.7
3.3
6.5
1.6
3.7%
Impairments (net)**
-0.6
0.0
-0.6
0.0
-0.6
10.5
10.5
9.9
0.0
-100.0%
Total depreciation and amortization
72.9
76.2
149.1
70.2
219.4
100.6
170.9
320.0
88.3
21.1%
EBITDA
592.6
692.0
1,284.6
723.4
2,008.1
536.5
1,259.9
2,544.6
706.3
19.2%
Adjustments
Acquisition costs
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Restructuring costs
Restructuring costs
-7.3
12.0
4.7
2.6
7.3
24.2
26.8
31.6
5.3
n.m.
Total
-7.3
12.0
4.7
2.6
7.3
24.2
26.8
31.6
5.3
n.m.
Integration costs/IT costs
Integration Cost
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
ERP/HR systems
4.0
3.5
7.4
5.1
12.5
7.2
12.3
19.7
1.1
-72.0%
Total
4.0
3.5
7.4
5.1
12.5
7.2
12.3
19.7
1.1
-72.0%
Gain (-)/ losses (+) on the divestment of businesses
Sale of Kuvan and Biosimilars
0.0
-7.6
-7.6
-50.5
-58.1
-4.0
-54.5
-62.1
-4.8
>1.000%
Sale of Consumer Health
0.0
4.3
4.3
4.7
9.0
0.6
5.3
9.6
0.0
3.2%
Sale of Allergopharma
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Others
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Total
0.3
-3.9
-3.6
-45.8
-49.4
-3.4
-49.2
-52.8
-4.8
n.m.
Other one-time costs
Others
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Total
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Total adjustments
-3.0
11.6
8.6
-38.1
-29.5
28.0
-10.1
-1.5
1.7
n.m.
EBITDA pre
589.6
703.6
1,293.2
685.4
1,978.5
564.5
1,249.9
2,543.1
708.0
20.1%
Due to rounding the sum of individual values may not add up to totals presented.
* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.
** Only reflects impairments classified as adjustments.
Electronics
Income Statement Merck KGaA, Darmstadt, Germany
Electronics
2023
2024
Change YoY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Net sales
900.7
899.3
1,800.0
915.9
2,715.9
943.2
1,859.1
3,659.2
928.4
3.1%
Cost of sales
-525.8
-572.2
-1,097.9
-592.2
-1,690.1
-641.9
-1,234.1
-2,332.0
-580.1
10.3%
thereof amortization of intangible assets
-33.6
-31.5
-65.2
-30.9
-96.1
-30.3
-61.2
-126.4
-30.0
-10.8%
Gross profit
374.9
327.2
702.1
323.7
1,025.8
301.3
625.0
1,327.2
348.3
-7.1%
in % of net sales
41.6%
36.4%
39.0%
35.3%
37.8%
31.9%
33.6%
36.3%
37.5%
SG&A
-215.1
-142.5
-357.7
-196.7
-554.3
-227.9
-424.6
-782.2
-180.0
-16.3%
in % of net sales
23.9%
15.8%
19.9%
21.5%
20.4%
24.2%
22.8%
21.4%
19.4%
Marketing and selling expenses
-158.2
-147.6
-305.8
-143.7
-449.5
-141.3
-285.0
-590.8
-137.7
-12.9%
thereof amortization of intangible assets (M&S)
-49.5
-48.2
-97.6
-48.1
-145.8
-49.3
-97.4
-195.0
-45.6
-7.9%
Administration expenses
-33.0
-35.1
-68.1
-40.0
-108.0
-39.1
-79.1
-147.1
-37.2
12.8%
Impairment losses and reversals (IFRS 9)
-0.1
-0.1
-0.2
0.1
-0.1
0.0
0.1
-0.1
0.1
n.m.
Other operating expenses/income
-23.8
40.2
16.4
-13.1
3.3
-47.5
-60.6
-44.2
-5.2
-78.3%
Impairments**
-10.3
-5.0
-15.3
-3.7
-18.9
-23.3
-27.0
-42.3
-0.5
-95.3%
Research and development costs
-74.1
-74.5
-148.7
-74.7
-223.4
-74.0
-148.7
-297.4
-73.1
-1.5%
in % of net sales
8.2%
8.3%
8.3%
8.2%
8.2%
7.8%
8.0%
8.1%
7.9%
thereof amortization of intangible assets (R&D)
-1.0
-0.9
-1.9
-1.0
-3.0
-1.2
-2.3
-4.2
-1.1
19.5%
EBIT
85.7
110.1
195.8
52.3
248.1
-0.5
51.7
247.5
95.2
11.1%
in % of net sales
9.5%
12.2%
10.9%
5.7%
9.1%
-0.1%
2.8%
6.8%
10.3%
Depreciation and amortization
142.6
134.7
277.3
133.5
410.8
157.4
290.9
568.2
129.8
-9.0%
EBITDA
228.2
244.8
473.1
185.8
658.8
156.9
342.6
815.7
224.9
-1.4%
in % of net sales
25.3%
27.2%
26.3%
20.3%
24.3%
16.6%
18.4%
22.3%
24.2%
EBITDA pre
237.3
261.7
499.1
207.9
707.0
206.0
413.9
913.0
236.6
-0.3%
in % of net sales
26.4%
29.1%
27.7%
22.7%
26.0%
21.8%
22.3%
25.0%
25.5%
Reconciliation to EBITDA pre
EBITDA
228.2
244.8
473.1
185.8
658.8
156.9
342.6
815.7
224.9
-1.4%
Adjustments
thereof: Cost of Sales
2.0
5.9
8.0
7.3
15.3
21.8
29.1
37.1
3.2
58.2%
thereof: Marketing and selling expenses
0.0
0.5
0.5
2.0
2.5
0.8
2.8
3.3
0.1
>1.000%
thereof: Administration expenses
2.0
3.6
5.7
7.7
13.3
15.4
23.1
28.7
4.7
135.0%
thereof: Other operating expenses/income
5.1
6.4
11.5
4.9
16.4
11.0
16.0
27.5
3.4
-33.7%
thereof: Research and development
-0.1
0.5
0.4
0.3
0.7
0.1
0.4
0.8
0.2
n.m.
Total
9.1
16.9
26.0
22.1
48.1
49.2
71.3
97.3
11.7
28.3%
EBITDA pre
237.3
261.7
499.1
207.9
707.0
206.0
413.9
913.0
236.6
-0.3%
Due to rounding the sum of individual values may not add up to totals presented.
** Only reflects impairments classified as adjustments.
Reconc. Electronics
Detailed reconciliation - Electronics
2023
2024
Change YoY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
EBIT
85.7
110.1
195.8
52.3
248.1
-0.5
51.7
247.5
95.2
11.1%
Regular depreciation and amortization*
48.2
49.1
97.3
49.7
147.0
53.3
103.0
200.3
52.5
9.0%
Impairments not adjusted
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.2
>1.000%
Amortization of purchased intangible assets
84.1
80.6
164.7
80.1
244.8
80.8
160.8
325.6
76.8
-8.7%
Impairments (net)**
10.3
5.0
15.3
3.7
18.9
23.3
27.0
42.3
0.5
-95.3%
Total depreciation and amortization
142.6
134.7
277.3
133.5
410.8
157.4
290.9
568.2
129.8
-9.0%
EBITDA
228.2
244.8
473.1
185.8
658.8
156.9
342.6
815.7
224.9
-1.4%
Adjustments
Acquisition costs
4.2
5.1
9.2
3.7
12.9
0.0
3.6
12.9
1.4
-65.8%
Restructuring costs
Restructuring costs
2.2
6.9
9.1
9.9
18.9
41.0
50.9
60.0
4.1
88.8%
Total
2.2
6.9
9.1
9.9
18.9
41.0
50.9
60.0
4.1
88.8%
Integration costs/IT costs
Integration Cost
1.1
1.0
2.1
1.2
3.3
0.5
1.6
3.8
1.1
1.2%
ERP/HR systems
1.7
3.9
5.6
7.4
13.0
7.7
15.1
20.7
5.1
203.6%
Total
2.8
4.9
7.7
8.6
16.3
8.2
16.8
24.5
6.2
121.9%
Gain (-)/ losses (+) on the divestment of businesses
Costs related to former business activities
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Total
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Other one-time costs
Others
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Total
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Total adjustments
9.1
16.9
26.0
22.1
48.1
49.2
71.3
97.3
11.7
28.3%
EBITDA pre
237.3
261.7
499.1
207.9
707.0
206.0
413.9
913.0
236.6
-0.3%
Due to rounding the sum of individual values may not add up to totals presented.
* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.
** Only reflects impairments classified as adjustments.
Corporate and Other
Income Statement Merck KGaA, Darmstadt, Germany
Corporate and Other
2023
2024
Change YoY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Net sales
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Cost of sales
-0.9
-2.6
-3.5
1.6
-1.9
-1.4
0.3
-3.2
0.3
n.m.
thereof amortization of intangible assets
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Gross profit
-0.9
-2.6
-3.5
1.6
-1.9
-1.4
0.3
-3.2
0.3
n.m.
SG&A
-217.8
-183.9
-401.7
-95.4
-497.1
-118.3
-213.6
-615.3
-145.0
-33.4%
Marketing and selling expenses
-2.8
-3.1
-5.9
0.5
-5.4
-1.9
-1.4
-7.3
-0.5
-81.0%
thereof amortization of intangible assets (M&S)
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-1.2%
Administration expenses
-144.4
-127.9
-272.3
-90.5
-362.8
-143.4
-233.9
-506.2
-107.4
-25.6%
Impairment losses and reversals (IFRS 9)
0.0
0.0
0.0
0.0
0.0
-7.6
-7.6
-7.6
0.0
-80.5%
Other operating expenses/income
-70.6
-52.9
-123.5
-5.4
-128.9
34.6
29.2
-94.3
-37.2
-47.4%
Impairments**
0.0
0.0
0.0
-0.1
-0.1
-1.2
-1.3
-1.3
0.0
n.m.
Research and development costs
-24.1
-25.3
-49.4
-24.7
-74.0
-20.4
-45.1
-94.4
-14.6
-39.3%
thereof amortization of intangible assets (R&D)
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
EBIT
-242.8
-211.7
-454.5
-118.4
-572.9
-140.0
-258.5
-713.0
-159.3
-34.4%
Depreciation and amortization
28.4
28.2
56.6
26.9
83.5
26.7
53.6
110.2
28.1
-1.2%
EBITDA
-214.4
-183.5
-397.9
-91.5
-489.4
-113.4
-204.9
-602.8
-131.3
-38.8%
EBITDA pre
-140.5
-123.9
-264.5
-62.7
-327.2
-69.5
-132.3
-396.7
-101.9
-27.5%
Reconciliation to EBITDA pre
EBITDA
-214.4
-183.5
-397.9
-91.5
-489.4
-113.4
-204.9
-602.8
-131.3
-38.8%
Adjustments
thereof: Cost of Sales
0.2
0.4
0.6
0.0
0.7
-0.1
0.0
0.6
0.0
-100.0%
thereof: Marketing and selling expenses
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
thereof: Administration expenses
54.6
22.8
77.5
12.2
89.6
54.5
66.7
144.2
20.0
-63.4%
thereof: Other operating expenses/income
19.0
35.0
54.0
16.6
70.6
-10.5
6.1
60.1
9.6
-49.8%
thereof: Research and development
0.0
1.3
1.3
0.0
1.3
-0.2
-0.1
1.2
-0.2
n.m.
Total
73.9
59.6
133.5
28.8
162.2
43.9
72.6
206.1
29.4
-60.3%
EBITDA pre
-140.5
-123.9
-264.5
-62.7
-327.2
-69.5
-132.3
-396.7
-101.9
-27.5%
Due to rounding the sum of individual values may not add up to totals presented.
** Only reflects impairments classified as adjustments.
Reconc. Corporate and Other
Detailed reconciliation - Corporate and Others
2023
2024
Change YoY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
EBIT
-242.8
-211.7
-454.5
-118.4
-572.9
-140.0
-258.5
-713.0
-159.3
-34.4%
Regular depreciation and amortization*
28.4
28.2
56.6
26.8
83.4
25.4
52.2
108.8
28.1
-1.2%
Impairments not adjusted
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Amortization of purchased intangible assets
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-1.2%
Impairments (net)**
0.0
0.0
0.0
0.1
0.1
1.2
1.3
1.3
0.0
n.m.
Total depreciation and amortization
28.4
28.2
56.6
26.9
83.5
26.7
53.6
110.2
28.1
-1.2%
EBITDA
-214.4
-183.5
-397.9
-91.5
-489.4
-113.4
-204.9
-602.8
-131.3
-38.8%
Adjustments
Acquisition costs
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Restructuring costs
Restructuring costs
49.0
18.5
67.6
7.9
75.4
52.0
59.8
127.4
17.2
-65.0%
Total
49.0
18.5
67.6
7.9
75.4
52.0
59.8
127.4
17.2
-65.0%
IT project costs
Integration Cost
0.0
0.1
0.1
0.1
0.2
0.1
0.2
0.3
0.1
ERP/HR systems
5.6
6.8
12.4
4.9
17.3
3.6
8.5
20.9
2.7
-51.1%
Total
5.6
6.9
12.5
5.0
17.5
3.7
8.7
21.2
2.8
-49.9%
Gain (-)/ losses (+) on the divestment of businesses
Costs related to former business activities
0.0
21.0
21.0
-3.0
18.0
-16.6
-19.6
1.4
0.0
n.m.
Total
0.0
21.0
21.0
-3.0
18.0
-16.6
-19.6
1.4
0.0
n.m.
Other one-time costs
Others
19.2
13.2
32.4
18.9
51.3
4.8
23.7
56.1
9.4
-51.2%
Total
19.2
13.2
32.4
18.9
51.3
4.8
23.7
56.1
9.4
-51.2%
Total adjustments
73.9
59.6
133.5
28.8
162.2
43.9
72.6
206.1
29.4
-60.3%
EBITDA pre
-140.5
-123.9
-264.5
-62.7
-327.2
-69.5
-132.3
-396.7
-101.9
-27.5%
Due to rounding the sum of individual values may not add up to totals presented.
* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.
** Only reflects impairments classified as adjustments.
Financial result
Income Statement Merck KGaA, Darmstadt, Germany
Group
2023
2024
Change YoY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Financial result
-22.7
-75.7
-98.4
-46.0
-144.3
19.1
-26.8
-125.2
-32.2
42.1%
Interest result
-27.4
-48.7
-76.1
-39.2
-115.3
15.3
-23.8
-100.0
-22.1
-19.4%
Interest income
20.6
36.7
57.3
25.0
82.2
70.8
95.8
153.0
28.1
36.4%
Interest expenses
-48.0
-85.4
-133.4
-64.1
-197.5
-55.4
-119.6
-253.0
-50.1
4.5%
Result from financial investments
13.4
7.4
20.8
12.7
33.5
10.6
23.2
44.1
7.3
-46.0%
Currency difference - financing
-1.4
-4.8
-6.3
5.6
-0.6
-0.4
5.3
-1.0
6.4
n.m.
Interest quota - pensions and other provisions
-7.3
-29.5
-36.8
-25.1
-61.9
-6.4
-31.5
-68.3
-23.8
227.0%
Others
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-86.7%
Due to rounding the sum of individual values may not add up to totals presented.
Cash Flow Statement Q
Cash Flow Statement Merck KGaA, Darmstadt, Germany
Group
2023
2024
Change YoY
€ million
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Q1
Q2
H1
Q3
9M
Q4
H2
FY
Profit after tax
799.7
706.1
1,505.8
740.4
2,246.2
587.6
1,328.0
2,833.8
699.5
-12.5%
Depreciation/amortization/impairment losses/reversals of impairment losses
455.5
482.3
937.8
435.2
1,373.0
506.7
941.9
1,879.7
453.5
-0.4%
of tangible assets
216.6
216.7
433.3
224.3
657.6
259.6
483.9
917.2
231.5
6.9%
of intangible assets
238.9
265.6
504.5
210.9
715.4
247.1
458.0
962.6
222.0
-7.1%
Changes in working capital
-223.9
-52.9
-276.8
-35.2
-312.0
171.5
136.3
-140.5
-177.4
-20.8%
Changes in inventories
-322.5
-106.3
-428.9
91.8
-337.0
248.3
340.2
-88.7
-40.9
-87.3%
Changes in trade accounts receivable
-116.5
14.7
-101.8
51.8
-50.0
41.6
93.3
-8.5
-64.0
-45.0%
Changes in trade accounts payable/ refund liabilities
215.1
38.8
253.9
-178.8
75.1
-118.5
-297.2
-43.4
-72.5
n.m.
Changes in provisions
-8.0
53.3
45.3
30.2
75.5
112.9
143.1
188.4
40.0
n.m.
Changes in other assets and liabilities
-187.0
-421.0
-608.0
143.1
-464.9
-290.1
-147.1
-755.1
32.6
n.m.
Neutralization of gain/loss on disposal of fixed assets and other disposals
-0.2
-145.5
-145.7
-7.0
-152.7
2.4
-4.6
-150.3
-7.9
>1.000%
Other non-cash income and expenses
16.5
0.1
16.7
-51.3
-34.6
-37.8
-89.1
-72.4
-5.0
n.m.
Operating Cash Flow
852.7
622.4
1,475.2
1,255.4
2,730.6
1,053.1
2,308.5
3,783.7
1,035.1
21.4%
thereof: from discontinued operations
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Payments for investments in intangible assets
-79.0
-30.9
-109.9
-33.7
-143.5
-72.6
-106.3
-216.2
-248.0
214.0%
Payments from the disposal of intangible assets
4.4
125.8
130.2
4.9
135.0
0.8
5.6
135.8
5.9
35.4%
Payments for investments in property, plant and equipment
-572.3
-295.6
-867.9
-428.4
-1,296.3
-511.0
-939.4
-1,807.4
-522.8
-8.6%
Payments from the disposal of property, plant and equipment
10.1
3.3
13.4
4.2
17.6
1.1
5.4
18.7
10.7
5.8%
Payments for acquisitions less acquired cash and cash equivalents (net)
0.1
0.1
0.1
-9.4
-9.3
-2.5
-11.9
-11.8
0.0
-100.0%
Payments from other divestments
-0.1
-0.2
-0.2
0.0
-0.2
0.0
0.0
-0.2
6.3
n.m.
Payments for investments in financial assets
-21.9
-12.2
-34.1
-58.8
-92.9
-444.3
-503.1
-537.2
-87.5
300.0%
Proceeds from the disposal of other financial assets
224.5
42.9
267.5
167.0
434.4
75.4
242.3
509.8
346.7
54.4%
Payments for the acquisition of non-financial assets
-897.0
-1,107.1
-2,004.1
-300.0
-2,304.2
-190.0
-490.1
-2,494.2
-200.0
-77.7%
Proceeds from the disposal of non-financial assets
100.0
1,414.1
1,514.1
303.9
1,818.0
692.8
996.7
2,510.8
0.0
-100.0%
Investing Cash Flow
-1,231.1
140.2
-1,091.0
-350.3
-1,441.3
-450.5
-800.8
-1,891.8
-688.7
-44.1%
thereof: from discontinued operations
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Dividend payments to Merck KGaA shareholders
0.0
-284.3
-284.3
0.0
-284.3
0.0
0.0
-284.3
0.0
n.m.
Dividend payments to non-controlling interests
0.0
-10.3
-10.3
-0.3
-10.6
-1.1
-1.4
-11.7
0.0
n.m.
Profit withdrawal by E.Merck KG
-90.4
-777.6
-868.0
0.0
-868.0
0.0
0.0
-868.0
-52.3
-42.1%
Changes in financial liabilities to E. Merck KG and E. Merck Beteiligungen KG
-0.8
697.8
697.1
-100.0
597.1
-320.4
-420.4
276.7
-26.9
>1.000%
Other changes in net equity
0.0
0.0
0.0
0.1
0.1
0.2
0.3
0.3
-0.1
>1.000%
Changes in current and non-current financial liabilities
215.6
-206.0
9.7
-202.2
-192.5
-652.7
-854.9
-845.3
-27.6
n.m.
Other changes from financing activities
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Financing Cash Flow
124.5
-580.4
-455.9
-302.4
-758.3
-974.0
-1,276.4
-1,732.3
-106.9
n.m.
thereof: from discontinued operations
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Changes in cash and cash equivalents
-254.0
182.2
-71.7
602.7
530.9
-371.3
231.3
159.6
239.5
n.m.
Changes in cash and cash equivalents due to currency translation
-15.7
-5.3
-21.1
1.7
-19.3
-12.1
-10.4
-31.4
-2.0
-87.5%
Cash and cash equivalents as of January 1st
1,853.8
0.0
1,853.8
0.0
1,853.8
0.0
0.0
1,853.8
1,982.0
6.9%
Cash and cash equivalents
1,584.1
176.9
1,761.0
604.4
2,365.4
-383.4
221.0
1,982.0
2,219.6
40.1%
Changes in cash and cash equivalents due to change in scope of consolidation
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
n.m.
Due to rounding the sum of individual values may not add up to totals presented.
Balance Sheet
Balance Sheet Merck KGaA, Darmstadt, Germany
Group
2023
2024
Shares of Totals
2011
Shares of Totals
2012
€ million
31-Mar
30-Jun
30-Sep
31. Dez
31-Mar
30-Jun
30-Sep
31-Dec
31-Mar
30-Jun
30-Sep
31. Dez
31-Mar
30-Jun
30-Sep
31-Dec
Non-current assets
35,686.3
35,763.3
36,339.9
36,102.3
36,680.9
73.4%
73.3%
72.8%
74.4%
74.1%
Goodwill
18,077.4
18,102.2
18,466.3
17,844.9
18,180.8
37.2%
37.1%
37.0%
36.8%
36.7%
Other intangible assets
6,953.8
6,765.2
6,716.5
6,551.3
6,480.6
14.3%
13.9%
13.5%
13.5%
13.1%
Property, plant and equipment
8,217.9
8,393.4
8,719.2
9,055.9
9,214.4
16.9%
17.2%
17.5%
18.7%
18.6%
Investments accounted for using the equity method
2.9
2.9
3.0
2.9
2.9
0.0%
0.0%
0.0%
0.0%
0.0%
Other non-current receivables
23.9
23.2
24.4
27.5
26.9
0.0%
0.0%
0.0%
0.1%
0.1%
Other non-current financial assets
958.9
1,040.9
989.8
980.8
1,067.7
2.0%
2.1%
2.0%
2.0%
2.2%
Other non-current non-financial assets
99.6
88.1
96.3
115.3
138.1
0.2%
0.2%
0.2%
0.2%
0.3%
Non-current income tax receivables
9.3
9.2
9.3
9.2
9.1
0.0%
0.0%
0.0%
0.0%
0.0%
Deferred tax assets
1,342.5
1,338.2
1,315.1
1,514.3
1,560.4
2.8%
2.7%
2.6%
3.1%
3.2%
Current assets
12,950.7
13,018.7
13,566.4
12,393.2
12,823.5
26.6%
26.7%
27.2%
25.6%
25.9%
Inventories
4,889.6
4,995.8
4,971.1
4,636.9
4,716.4
10.1%
10.2%
10.0%
9.6%
9.5%
Trade and other current receivables
4,269.8
4,209.8
4,195.1
4,003.9
4,147.1
8.8%
8.6%
8.4%
8.3%
8.4%
Contract assets
132.6
126.5
122.1
103.7
99.1
0.3%
0.3%
0.2%
0.2%
0.2%
Other current financial assets
136.8
166.3
218.3
499.1
264.1
0.3%
0.3%
0.4%
1.0%
0.5%
Other current non-financial assets
1,515.8
1,250.0
1,140.2
632.5
942.4
3.1%
2.6%
2.3%
1.3%
1.9%
Current income tax receivables
421.9
509.2
554.2
472.8
434.8
0.9%
1.0%
1.1%
1.0%
0.9%
Cash and cash equivalents
1,584.1
1,761.0
2,365.4
1,982.0
2,219.6
3.3%
3.6%
4.7%
4.1%
4.5%
Assets held for sale
0.0
0.0
0.0
62.3
0.0
0.0%
0.0%
0.0%
0.1%
0.0%
Total assets
48,637.0
48,781.9
49,906.2
48,495.4
49,504.4
100.0%
100.0%
100.0%
100.0%
100.0%
Total equity
26,230.0
26,771.9
28,294.5
26,754.31
28,074.2
53.9%
54.9%
56.7%
55.2%
56.7%
Equity capital
565.2
565.2
565.2
565.2
565.2
1.2%
1.2%
1.1%
1.2%
1.1%
Capital reserves
3,813.7
3,813.7
3,813.7
3,813.73
3,813.7
7.8%
7.8%
7.6%
7.9%
7.7%
Retained earnings
19,250.0
19,760.5
20,710.7
20,228.20
21,031.1
39.6%
40.5%
41.5%
41.7%
42.5%
Gain/losses recognized in equity
2,520.3
2,561.2
3,132.2
2,072.6
2,585.9
5.2%
5.3%
6.3%
4.3%
5.2%
Non-controlling interest
80.7
71.3
72.7
74.53
78.2
0.2%
0.1%
0.1%
0.2%
0.2%
Non-current liabilities
12,850.8
13,163.9
12,926.3
13,041.7
11,491.1
26.4%
27.0%
25.9%
26.9%
23.2%
Non-current provisions for employee benefits
1,965.3
1,994.5
1,773.6
2,192.0
2,132.9
4.0%
4.1%
3.6%
4.5%
4.3%
Other non-current provisions
307.0
294.1
276.0
277.4
262.7
0.6%
0.6%
0.6%
0.6%
0.5%
Non-current financial debt
9,159.3
9,495.4
9,540.5
9,239.5
7,822.5
18.8%
19.5%
19.1%
19.1%
15.8%
Other non-current financial liabilities
142.4
141.3
142.8
147.1
150.5
0.3%
0.3%
0.3%
0.3%
0.3%
Other non-current non-financial liabilities
19.3
19.0
18.2
16.5
16.3
0.0%
0.0%
0.0%
0.0%
0.0%
Non-current income tax liabilities
38.0
37.5
41.0
39.5
39.4
0.1%
0.1%
0.1%
0.1%
0.1%
Deferred tax liabilities
1,219.4
1,182.1
1,134.3
1,129.6
1,066.7
2.5%
2.4%
2.3%
2.3%
2.2%
Current liabilities
9,556.2
8,846.1
8,685.4
8,699.4
9,939.1
19.6%
18.1%
17.4%
17.9%
20.1%
Current provisions for employee benefits
131.6
105.9
124.4
82.9
81.3
0.3%
0.2%
0.2%
0.2%
0.2%
Other current provisions
378.8
448.1
469.0
575.0
594.0
0.8%
0.9%
0.9%
1.2%
1.2%
Current financial debt
1,484.9
1,690.1
1,415.7
701.5
2,130.5
3.1%
3.5%
2.8%
1.4%
4.3%
Other current financial liabilities
1,017.3
259.1
241.8
1,005.1
994.4
2.1%
0.5%
0.5%
2.1%
2.0%
Trade and other current payables
2,326.1
2,402.7
2,243.8
2,545.4
2,086.0
4.8%
4.9%
4.5%
5.2%
4.2%
Refund liabilities
947.1
963.1
990.0
876.8
880.9
1.9%
2.0%
2.0%
1.8%
1.8%
Current income tax liabilities
1,461.4
1,487.8
1,580.7
1,433.4
1,564.9
3.0%
3.0%
3.2%
3.0%
3.2%
Other current non-financial liabilities
1,809.1
1,489.4
1,620.1
1,479.4
1,607.1
3.7%
3.1%
3.2%
3.1%
3.2%
Liabilities included in disposal groups classified as held for sale
0.0
0.0
0.0
0.0
0.0
0.0%
0.0%
0.0%
0.0%
0.0%
Total liabilities and stockholders' equity
48,637.0
48,781.9
49,906.2
48,495.4
49,504.4
100.0%
100.0%
100.0%
100.0%
100.0%
2023
2024
Shares of Totals
2011
Shares of Totals
2012
31-Mar
30-Jun
30-Sep
31. Dez
31-Mar
30-Jun
30-Sep
31-Dec
31-Mar
30-Jun
30-Sep
31. Dez
31-Mar
30-Jun
30-Sep
31-Dec
Financial debt
10,644.2
11,185.5
10,956.2
9,941.0
9,953.0
21.9%
22.9%
22.0%
20.5%
20.1%
Net financial debt
8,991.9
9,354.9
8,426.5
7,500.0
7,497.9
18.5%
19.2%
16.9%
15.5%
15.1%
Additions to Property, plant and equipment (excl. Leasing)1
297.9
669.6
1,108.0
1,775.2
305.3
n.m.
n.m.
n.m.
n.m.
n.m.
Due to rounding the sum of individual values may not add up to totals presented.
1 Figures are year-to-date figures from January 1st until stated end date.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Merck KGaA published this content on
16 May 2024 and is solely responsible for the information contained therein. Distributed by
Public , unedited and unaltered, on
16 May 2024 16:52:05 UTC .
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows:
- solutions and products for scientific and biotechnological research (44.2%);
- pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.;
- performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc.
Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
More about the company
Last Close Price
166.5
EUR
Average target price
184.8
EUR
Spread / Average Target
+11.00%
Consensus
1st Jan change
Capi.
+15.54% 78.51B +12.05% 9B +58.17% 4.96B -14.94% 4.84B -.--% 3.72B +21.94% 2.48B -26.63% 2.19B +16.75% 2.12B -37.97% 1.94B -0.50% 1.64B
Specialty & Advanced Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1